

Lipum receives Vinnova funding for biomarker-guided development of SOL-116

Lipum AB has been awarded SEK 499 000 by Vinnova, to develop a biomarker strategy for the future clinical development of SOL-116 in chronic inflammatory diseases. The Swedish-German project will be conducted together with the German biotechnology company Clairvoyant Diagnostics GmbH and will run from October 2026 to March 2027.

The project brings together complementary expertise from the two companies. Lipum contributes its knowledge of Bile Salt-Stimulated Lipase (BSSL), therapeutic development and clinical strategy. Clairvoyant Diagnostics adds expertise in biomarker discovery, translational immunology, autoantibody profiling, protein-array technologies and diagnostic development.

The collaboration will identify the most promising biomarkers for SOL-116 and explore how they could be used in future studies. This may help improve the understanding of treatment response and support patient stratification. The initial focus will be rheumatoid arthritis, while the potential of BSSL inhibition in other chronic inflammatory diseases may be explored in the longer term.

“This funding enables us to deepen our collaboration with Clairvoyant Diagnostics and create a joint framework for future biomarker and translational studies. A stronger understanding of biomarkers and the mechanism of action of SOL-116 may support future clinical development and the continued positioning of SOL-116 in rheumatoid arthritis and other chronic inflammatory diseases,” says Ola Sandborgh, CEO at Lipum.

During the six-month project, the partners will establish a formal framework for collaboration and governance, evaluate scientific and technical opportunities and prioritize future biomarker and study concepts. We will also agree on principles for intellectual property and data sharing and develop a roadmap and funding strategy for continued Swedish-German and European research and innovation initiatives.

The activities funded within the project are focused on collaboration building, feasibility assessment and strategic planning. The total project budget is SEK 591 000 of which 499 000 is financed by Vinnova

Contacts

Ola Sandborgh, CEO

ola.sandborgh@lipum.se

+46 72 218 80 21

Web: www.lipum.se

PRESS RELEASE

29 September 2026 09:15:00 CEST

**About Us**

Lipum AB based in Umeå, is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. Lipum's unique approach has attracted international attention and has been awarded EUR 8 million in EU funding for the Horizon Europe project BEYOND.

Attachments

[Lipum receives Vinnova funding for biomarker-guided development of SOL-116](#)